Showing 4451-4460 of 6411 results for "".
- Lasers May Treat Burn Scars of Military, Civilianshttps://practicaldermatology.com/news/20120420-lasers_may_treat_burn_scars_of_military_civilians/2459817/Fractional laser procedures may offer a treatment option for the estimated 1 million American who survive serious burn injuries each year, according to experts presenting at the ASLMS Annual Meeting in Kissimmee, FL. According to Jill Waibel, MD, credited with performing one of (or pe
- "Skin Rules" Hits Market March 13https://practicaldermatology.com/news/20120307-skin_rules_hits_market_march_13/2459854/Skin Rules (St. Martin's Press), a new book by dermatologist Debra Jaliman, MD, goes on sale March 13. According to a release, the book "lays out clear, easy-to-understand information on the latest technologies, such as Cool Sculpting (body co
- From EADV: Rezpegaldesleukin Effective Through 24 Weeks in REZOLVE-AD Trialhttps://practicaldermatology.com/news/from-eadv-rezpegaldesleukin-effective-through-24-weeks-in-rezolve-ad-trial/2483465/New data from the REZOLVE-AD presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress demonstrated that investigational IL-2 pathway agonist rezpegaldesleukin sustained effect beyond the 16-week induction period in patients with moderat
- From EADV: Bimekizumab Shows Sustained Efficacy in Plaque Psoriasis and HShttps://practicaldermatology.com/news/from-eadv-bimekizumab-shows-sustained-efficacy-in-plaque-psoriasis-and-hs/2483464/New data presented by UCB at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris both showed sustained efficacy and tolerability for BIMZELX® (bimekizumab-bkzx) in both moderate-to-severe hidradenitis suppurativa (HS) and plaque psorias
- FDA Clears IND for Rubedo’s GPX4 Modulator in Actinic Keratosishttps://practicaldermatology.com/news/fda-clears-ind-for-rubedos-gpx4-modulator-in-actinic-keratosis/2483388/Rubedo Life Sciences has received FDA clearance for a second Investigational New Drug (IND) application for its lead compound RLS-1496, enabling a Phase 1b/2a trial in patients with actinic keratosis to begin in Q4 2025. Accordi
- Psoriatic Disease Tied to Elevated APS Incidence: Studyhttps://practicaldermatology.com/news/psoriatic-disease-tied-to-elevated-aps-incidence-study/2483386/Data from a new cohort study has identified an increased risk of antiphospholipid syndrome (APS) in patients with psoriasis, particularly those with psoriatic arthritis (PsA). Researchers for the study matched 288,678 patients fro
- Analysis: IL-17, JAK Inhibitors May Carry Elevated Risk for TBhttps://practicaldermatology.com/news/analysis-il-17-jak-inhibitors-may-carry-elevated-risk-for-tb/2483387/A large population-based analysis using data from TriNetX suggests a elevated risk of active tuberculosis (TB) in patients treated with systemic immunosuppressive therapies (including IL-17, IL-23, IL-12/23, Janus kinase (JAK) inhibitors), cyclosporine, and tumor ne
- Galderma to Present Long-Term Nemluvio Data, Global Sensitive Skin Survey at EADV 2025https://practicaldermatology.com/news/galderma-to-present-long-term-nemluvio-data-global-sensitive-skin-survey-at-eadv-2025/2483331/Galderma will present new findings on sensitive skin, as well as long-term data on nemolizumab (Nemluvio®) at the 34th European Academy of Dermatology and Venereology (EADV) Congress, to be held in Paris, September 17–20, 2025, a press statement from the manufactur
- Incyte to Present STOP-HS, TRuE-PN Trials at EADV 2025https://practicaldermatology.com/news/late-breaking-hs-and-pn-data-to-anchor-incytes-eadv-presentations/2483330/Incyte announced that it will present new data from studies throughouts its dermatology pipeline at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, according to a press release from the manufacturer.
- Biologics Most Likely to Be Continued After MACE: Studyhttps://practicaldermatology.com/news/biologics-most-likely-to-be-continued-after-mace-study/2483287/Biologic therapies were linked with greater treatment persistence than non-biologic systemic agents or phototherapy among patients with psoriasis who experience major adverse cardiovascular events (MACE), according to findings from a retrospective study of Korean n